1h-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one has been researched along with Parkinsonian Disorders in 1 studies
1H-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one: structure given in first source; inhibits guanylyl cyclase
1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one : A member of the class of oxadiazoloquinoxalines that is 1H-[1,2,4]oxadiazolo[4,3-a]quinoxaline substituted at position 1 by an oxo group.
Parkinsonian Disorders: A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tseng, KY | 1 |
| Caballero, A | 1 |
| Dec, A | 1 |
| Cass, DK | 1 |
| Simak, N | 1 |
| Sunu, E | 1 |
| Park, MJ | 1 |
| Blume, SR | 1 |
| Sammut, S | 1 |
| Park, DJ | 1 |
| West, AR | 1 |
1 other study available for 1h-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one and Parkinsonian Disorders
| Article | Year |
|---|---|
Inhibition of striatal soluble guanylyl cyclase-cGMP signaling reverses basal ganglia dysfunction and akinesia in experimental parkinsonism.
Topics: Animals; Basal Ganglia; Corpus Striatum; Cyclic GMP; Enzyme Inhibitors; Guanylate Cyclase; Male; Mic | 2011 |